Email updates

Keep up to date with the latest news and content from BMC Musculoskeletal Disorders and BioMed Central.

Open Access Highly Accessed Pre-publication history

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

Daniel R Murphy*, Lee J Smolen, Timothy M Klein and Robert W Klein

  • * Corresponding author: Daniel R Murphy drm@mdm-inc.com

  • † Equal contributors

BMC Musculoskeletal Disorders 2012, 13:213  doi:10.1186/1471-2474-13-213

Pre-publication versions of this article and reviewers' reports

Original Submission - Version 1 Manuscript 24 Feb 2012
Resubmission - Version 2 Manuscript Author's comment 01 Mar 2012
Reviewer's Report Peter Vestergaard 03 May 2012
Reviewer's Report Jan Sorensen 04 May 2012
Resubmission - Version 3 Manuscript 18 Jun 2012
Resubmission - Version 4 Manuscript Author's comment 18 Jun 2012
Resubmission - Version 5 Manuscript 18 Jun 2012
Reviewer's Report Peter Vestergaard 22 Jun 2012
Reviewer's Report Jan Sorensen 06 Jul 2012
Resubmission - Version 6 Manuscript Author's comment 03 Oct 2012
Resubmission - Version 7 Manuscript Author's comment 04 Oct 2012
Editorial acceptance 09 Oct 2012
Published 30 Oct 2012